BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S; the Japanese Society of Renal Cancer. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era: Cytoreductive nephrectomy for Japanese patients. Int J Urol 2015;22:736-40. [DOI: 10.1111/iju.12803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Larcher A, Wallis CJ, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? European Urology Oncology 2019;2:365-78. [DOI: 10.1016/j.euo.2019.04.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
2 Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. Clinical Genitourinary Cancer 2016;14:465-72. [DOI: 10.1016/j.clgc.2016.04.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
3 García-Perdomo HA, Zapata-Copete JA, Castillo-Cobaleda DF. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis. Investig Clin Urol 2018;59:2-9. [PMID: 29333508 DOI: 10.4111/icu.2018.59.1.2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Targ Oncol 2018;13:705-14. [DOI: 10.1007/s11523-018-0601-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
5 Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology 2019;75:111-28. [DOI: 10.1016/j.eururo.2018.09.016] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 20.7] [Reference Citation Analysis]
6 Naito S, Kato T, Ichiyanagi O, Narisawa T, Kurokawa M, Yagi M, Ushijima M, Ozawa M, Kanno H, Kurota Y, Fukuhara H, Kuboki Y, Yamagishi A, Sakurai T, Nishida H, Yamanobe T, Tsuchiya N. New prognostic model for synchronous metastatic renal cell carcinoma. Int J Urol 2020;27:448-56. [DOI: 10.1111/iju.14215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Esagian SM, Ziogas IA, Kosmidis D, Hossain MD, Tannir NM, Msaouel P. Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. Cancers (Basel) 2021;13:695. [PMID: 33572149 DOI: 10.3390/cancers13040695] [Reference Citation Analysis]
8 Li C, Wang R, Ma W, Liu S, Yao X. Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database. Front Surg 2021;8:716455. [PMID: 34557516 DOI: 10.3389/fsurg.2021.716455] [Reference Citation Analysis]
9 Hong X, Li F, Tang K, Pang S, Lin G, Li S, Bao J, Tan W. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis. Int Urol Nephrol 2016;48:967-75. [PMID: 26861063 DOI: 10.1007/s11255-016-1233-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Naito S, Kato T, Tsuchiya N. Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. Int J Urol 2022. [PMID: 35340081 DOI: 10.1111/iju.14841] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Bigot P, Lebdai S, Azzouzi AR. Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. Int J Urol 2015;22:740-1. [PMID: 26012629 DOI: 10.1111/iju.12818] [Reference Citation Analysis]
12 Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Jpn J Clin Oncol 2021;51:296-304. [PMID: 32989464 DOI: 10.1093/jjco/hyaa171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shapiro DD, Westerman ME, Karam JA, Wood CG. Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question? Cancer J 2020;26:382-9. [PMID: 32947306 DOI: 10.1097/PPO.0000000000000470] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]